Breast Cancer Trial, Recruiting NCT06321653 Sponsor: European Institute of Oncology Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT06321653
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with invasive breast cancer confirmed by a tissue sample (biopsy)
  • People who have had breast-conserving surgery (where only the tumour and some surrounding tissue are removed, not the whole breast)
  • People whose tumour measured no more than 5 cm, and who had no more than 2 sentinel lymph nodes (the first nodes cancer might spread to) that tested positive for cancer
  • People whose surgical margins were clear, meaning no cancer cells were found at the edges of the removed tissue
  • People who are in reasonably good general health (confirm with trial site for specific health score details)
  • People aged 18 or older
  • People who are willing to provide written consent to participate

Who may not be able to join:

  • People who have previously had radiation therapy to the chest area
  • People who have certain connective tissue disorders (conditions affecting joints, skin, and other tissues)
  • People whose cancer has spread to other parts of the body (distant metastases)
  • People with serious lung or heart conditions
  • People who received chemotherapy or other systemic treatments before their surgery (neoadjuvant therapy)
  • People who had a full axillary lymph node dissection (removal of many lymph nodes from the armpit)
  • People who did not have any surgical investigation of the lymph nodes in the armpit
  • People who had a full mastectomy (complete removal of the breast)
  • People whose sentinel lymph nodes contained only very tiny amounts of cancer cells (micrometastasis or isolated tumour cells)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Maria Cristina Leonardi, MD, European Institute of Oncology

Phone: +39 02 94372156

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
European Institute of Oncology
Registry
ClinicalTrials.gov
Start date
18 April 2019
Est. completion
31 December 2024

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Percentage of patients with arm lymphedema

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov